We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $439M
1-Year Est. Return 289.78%
This Fund
S&P 500
This Quarter Est. Return
+35.32%
1 Year Est. Return
+289.78%
3 Year Est. Return
+622.25%
5 Year Est. Return
+856.34%
10 Year Est. Return
+2,866.87%
AUM
$439M
AUM Growth
+$76.4M
Cap. Flow
-$4.42M
Cap. Flow %
-1.01%
Top 10 Hldgs %
28.21%
Holding
185
New
29
Increased
50
Reduced
66
Closed
38

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$4.61M
2
ALKS icon
Alkermes
ALKS
+$4.14M
3
TNGX icon
Tango Therapeutics
TNGX
+$3.85M
4
RLMD icon
Relmada Therapeutics
RLMD
+$3.12M
5
ELVN icon
Enliven Therapeutics
ELVN
+$2.75M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$6.03M
2
NUVL
Nuvalent
NUVL
+$5.8M
3
SLNO
Soleno Therapeutics
SLNO
+$5.53M
4
SYRE icon
Spyre Therapeutics
SYRE
+$5M
5
APGE
Apogee Therapeutics
APGE
+$3.01M

Sector Composition

Rank Sector Weight
1 Healthcare 70.95%
2 Technology 8.26%
3 Miscellaneous 6.43%
4 Industrials 4.96%
5 Financials 2.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
126
UroGen Pharma
URGN
$2.16B
$919K 0.21%
24,968
-1,542
-6% -$41.8K
MSFT icon
127
Microsoft
MSFT
$3.71T
$900K 0.21%
2,413
-4,044
-63% -$1.64M
ZYME icon
128
Zymeworks
ZYME
$2.09B
$889K 0.2%
34,013
-72
-0.2% -$1.83K
AEIS icon
129
Advanced Energy
AEIS
$11.3B
$835K 0.19%
+2,240
New +$783K
KSPI icon
130
Kaspi.kz JSC
KSPI
$20.4B
$814K 0.19%
+9,400
New +$797K
HDB icon
131
HDFC Bank
HDB
$119B
$799K 0.18%
30,927
+4,800
+18% +$120K
VST icon
132
Vistra
VST
$50.1B
$777K 0.18%
+4,900
New +$760K
JANX icon
133
Janux Therapeutics
JANX
$1.24B
$743K 0.17%
48,376
-1,007
-2% -$14.6K
NAMS icon
134
NewAmsterdam Pharma
NAMS
$3.04B
$708K 0.16%
20,905
+838
+4% +$27.6K
META icon
135
Meta Platforms (Facebook)
META
$1.57T
$655K 0.15%
1,162
-580
-33% -$355K
MBX
136
MBX Biosciences
MBX
$2.97B
$642K 0.15%
11,634
+162
+1% +$5.66K
NU icon
137
Nu Holdings
NU
$74.2B
$641K 0.15%
47,970
-1,600
-3% -$21.6K
CTMX icon
138
CytomX Therapeutics
CTMX
$808M
$637K 0.15%
169,831
-118,226
-41% -$451K
MELI icon
139
Mercado Libre
MELI
$100B
$637K 0.15%
375
-60
-14% -$102K
CEG icon
140
Constellation Energy
CEG
$106B
$618K 0.14%
2,490
-3,262
-57% -$919K
NKTR icon
141
Nektar Therapeutics
NKTR
$2.53B
$608K 0.14%
8,708
-5,847
-40% -$428K
AKAM icon
142
Akamai
AKAM
$15.1B
$579K 0.13%
+4,900
New +$610K
XNCR icon
143
Xencor
XNCR
$1.98B
$432K 0.1%
26,822
-26,223
-49% -$328K
KYMR icon
144
Kymera Therapeutics
KYMR
$9.76B
$428K 0.1%
3,731
-54
-1% -$4.64K
PDD icon
145
Pinduoduo
PDD
$117B
$420K 0.1%
5,500
-1,400
-20% -$129K
JD icon
146
JD.com
JD
$38.2B
$361K 0.08%
14,163
+700
+5% +$20.6K
BBD icon
147
Banco Bradesco
BBD
$36.7B
$358K 0.08%
103,132
-105,132
-50% -$385K
AGX icon
148
Argan
AGX
$5.86B
– –
-1,896
Closed -$1.03M
APGE
149
DELISTED
Apogee Therapeutics
APGE
– –
-35,761
Closed -$3.01M
ASND icon
150
Ascendis Pharma A/S
ASND
$17.7B
– –
-5,781
Closed -$1.32M
4 5
6
7 8

Similar funds

OGM
OnyxPoint Global Management New York $439M AUM 52.19% 1-Year Est. Return
NCM
New Capital Management Houston, Texas $439M AUM 16.55% 1-Year Est. Return
BCC
Bridge City Capital Lake Oswego, Oregon $438M AUM 64.84% 1-Year Est. Return
ASW
Astoria Strategic Wealth Conroe, Texas $438M AUM 16.79% 1-Year Est. Return
CNC
Citizens & Northern Corp Wellsboro, Pennsylvania $438M AUM 26.63% 1-Year Est. Return
TAA
Turiya Advisors Asia Hong Kong $440M AUM 152.81% 1-Year Est. Return
PMA
Prudent Man Advisors Naperville, Illinois $438M AUM 34.49% 1-Year Est. Return
FW
Fairway Wealth Independence, Ohio $437M AUM 19.74% 1-Year Est. Return

HighVista Strategies's Q2 2026 Portfolio in Review

As of Q2 2026, HighVista Strategies held 185 positions worth $439M, up 21% from $362M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

HighVista Strategies's Q2 2026 filing shows 29 new, 50 increased, 66 reduced and 38 closed positions. Its largest new stake was C4 Therapeutics: 1,348,136 shares worth $6.3M. The largest sale was Terns Pharmaceuticals, an estimated $6.03M.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier, followed by Technology and Miscellaneous.

  • HighVista Strategies's largest Q2 2026 buy was C4 Therapeutics: 1,348,136 shares worth $6.3M.
  • HighVista Strategies added most to Alkermes in Q2 2026, an estimated $4.14M increase.
  • HighVista Strategies's biggest Q2 2026 reduction was Spyre Therapeutics, cutting an estimated $5M.
  • HighVista Strategies fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $6.03M.
  • HighVista Strategies's ten largest holdings make up 28% of its $439M portfolio in Q2 2026.
  • HighVista Strategies opened 29 new positions and closed 38 in Q2 2026.
  • HighVista Strategies's portfolio value rose 21% quarter-over-quarter to $439M.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.